(PRWEB) June 20, 2012
Mesoblast, one of the leading stem cell therapy development companies in the world today, noted in a presentation at the Jefferies Global Healthcare Conference in New York that the company will open a new treatment front based on the unique properties of dental pulp stem cells [DPSC]. CEO professor Silviu Itescu explained at the conference that dental stem cells are especially valuable because they are a type of mesenchymal stem cell known to produce more neurotrophic factors than other adult stem cell types. The cells have also demonstrated the ability to protect and repair neural tissue after spinal cord injury and stroke hence, Mesoblasts efforts will center around the development of treatments for stroke, spinal cord injuries, Parkinson’s, and Huntington’s diseases.
DPSCs are STRO-1 positive, meaning they tend to be more homogenous and have higher rates of adherence and proliferation than other mesenchymal progenitor cells [MPCs]. STRO-1 is a monoclonal antibody used in the sorting and identification of MPCs making them ideal candidates for regenerative treatments.
Mesoblast’s announcement is another example of the inherent plasticity and proliferative capabilities of DPSCs. These characteristics make dental stem cells particularly valuable to individuals and families. Dental stem cells are also easy to procure and preserve for use in future therapies. To learn more about how you can bank dental stem cells to ensure access to a variety of treatments and therapies, visit http://www.stemsave.com or call 877-783-6728 (877-StemSave) today.
The future of Regenerative Medicine is now.